Zurzuvae PPD denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Zurzuvae for Postpartum Depression as Duplicate Therapy

Zurzuvae (zuranolone) is an oral neuroactive steroid approved for postpartum depression (PPD). Aetna may issue a duplicate-therapy denial when another antidepressant is already active on the patient's medication profile — for example, an SSRI, SNRI, or another agent prescribed for depression. The insurer's utilization management system may flag the combination as therapeutically overlapping and decline to authorize a second agent for the same condition.

This denial is worth contesting. Zurzuvae has a distinct mechanism of action (positive allosteric modulation of GABA-A receptors) and a different clinical profile from conventional antidepressants. Your prescriber can document why concurrent or sequential use is clinically appropriate for this patient's specific presentation, severity, and treatment history. PPD can carry serious risk to both the patient and infant, and inadequate treatment is not a neutral outcome — this clinical urgency supports an expedited appeal.

## Your Appeal Rights

• Internal appeal: Submit a written internal appeal within the deadline stated on the denial letter (commonly 180 days for Aetna). Under ERISA §503 (employer plans) you are entitled to a full-and-fair review.
• External review (ACA §2719): After an adverse internal decision, you may request independent external review. The standard window is up to four months from the final internal denial. For urgent situations — including postpartum patients with severe symptoms — request expedited external review, which must be completed within 72 hours.
• Mental Health Parity (MHPAEA): Federal mental health parity law prohibits insurers from applying more restrictive utilization management criteria to mental health conditions than to comparable medical/surgical conditions. If Aetna's duplicate-therapy rule is applied more aggressively to PPD than to analogous physical-health drug combinations, this is a parity violation you can raise in your appeal.

## Documentation to Gather

1. Diagnosis confirmation — physician documentation of postpartum depression diagnosis with severity assessment and date of onset relative to delivery. 2. Prior treatment history — a complete log of all antidepressants and other treatments tried, including start/stop dates, doses (from the chart), and documented response or reason for discontinuation. 3. Clinical severity record — validated screening scores, clinical notes on functional impairment, and any documentation of risk to patient or infant. 4. Prescriber medical-necessity letter — your ob-gyn, psychiatrist, or prescribing physician should explain why Zurzuvae is not duplicative — addressing its distinct mechanism, its specific FDA-approved PPD indication, and why concurrent use is appropriate for this patient. 5. Applicable guideline reference — cite relevant guidance from the applicable professional organization (e.g., American College of Obstetricians and Gynecologists, American Psychiatric Association) supporting the treatment approach.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy bulletin for Zurzuvae and the FDA-approved prescribing label. For each listed criterion:

| Policy / Label Criterion | Chart Evidence with Date | |---|---| | Confirmed PPD diagnosis | Physician note, [date] | | Severity documentation | Screening assessment, [date] | | Prior treatment history and outcomes | Medication log with dates | | Clinical rationale for use alongside existing therapy | Prescriber letter, [date] |

The appeal should emphasize both the mechanistic distinction from other antidepressants and the time-sensitive nature of PPD treatment — delayed or inadequate treatment carries documented risks that a reviewer will recognize as clinically significant.